Risk factors
Amarin (AMRN) risk factors
Item 1A of every Amarin Corp. plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors73 risks10 new6 dropped17 reworded
Amarin relies heavily on its European partnership with Recordati for commercializing VAZKEPA across 59 countries.
Filed Mar 02, 2026 - FY2024 10-K risk factors69 risks
Amarin relies almost entirely on commercializing VASCEPA and VAZKEPA in the U.S. and Europe. Generic competition and ANDA litigation rulings have severely impacted U.S. revenues. International expansion faces stringent price controls, reimbursement hurdles, and reliance on third-party partners.
Filed Mar 12, 2025